Category Archives: Immunology

Immunology

Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN…

Acquisition brings critical technical pre-clinical vaccine development capabilities in-house and establishes US based Emergex subsidiary

Emergex uniquely develops novel 100% synthetic set-point T cell priming vaccines to address some of the worlds most pathogenic infectious diseases

Current COVID-19 pandemic and ongoing threat of pandemic flu demonstrate urgent global need for safe, effective vaccines which can be rapidly developed and deployed

Abingdon, UK, 1 September 2020 Emergex Vaccines Holding Limited (Emergex), a company tackling major global infectious disease threats through the development of synthetic set point vaccines which prime the T cell immune response, today announces that it has significantly strengthened its technology platform and formed US subsidiary, Emergex USA, by acquiring the laboratories, technology and assets of US-based biotech ImmProNano Inc. Financial details of the transaction were not disclosed.

ImmProNano (IPN), based in Doylestown, PA is a specialist contract research organization in the field of Human Leukocyte Antigen T cell immunology and immunoproteomics, utilizing state of the art mass-spectrometry to determine Class I major histocompatibility complex expression libraries of viral infected cells. These libraries are critical to the development of vaccines to high pathogen viruses and intracellular bacteria. IPN also has unparalleled expertise in the T cell immunology of infectious disease and T cell vaccine development.

IPN has completed all pre-clinical testing in animals and ex vivo human samples for Emergexs recent vaccine programs including Francisella tularensis, Yellow fever, Zika, Dengue, Influenza and COVID-19.

ImmProNanos laboratory facilities and key employees will now form Emergexs US subsidiary. The team will continue to work closely with Emergexs state of the art UK R&D facility and also form critical interactions with Emergexs other vaccine collaborators at George Mason University, USA and the Institute of Molecular and Cell Biology of Singapore (A*STAR).

Storme Moore-Thornicroft, co-founder and COO of Emergex, commented: ImmProNano has been a trusted partner for several years, their deep expertise in T cell immunology complementing our novel approach to vaccine development. This acquisition establishes a US base and brings together key elements of the vaccine development process in-house, an important next step as we look to advance promising vaccine candidates in areas including Dengue Fever, pandemic flu and other globally important infectious diseases. The critical need for the ability to develop and manufacture potent vaccines in a timely and cost-effective manner has never been clearer and todays agreement ensures Emergex is well placed to meet this goal.

Originally posted here:
Emergex Vaccines forms US subsidiary (Emergex USA) by acquisition of laboratories, technology and assets of US-based T cell specialist biotech ImmProN...

Immunology

Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Magenta Therapeutics (NASDAQ: MGTA), a clinical-stage biotechnology company developing novel medicines to bring the curative power of immune reset to more patients, today announced the appointment of two new executives, Lisa M. Olson, Ph.D., as Chief Scientific Officer and Kevin B. Johnson, Ph.D., as Senior Vice President, Head of Regulatory and Quality. The Company also announced that Jason Ryan will transition from Chief Operating and Financial Officer to a consulting role for personal reasons while a search for his replacement is conducted.

With the additions of Lisa and Kevin to our team, Magenta continues to deepen our technical expertise, bolstering our strong discovery, research, development and regulatory leadership to further our goal of delivering curative immune reset to patients in need, said Jason Gardner, D.Phil., Chief Executive Officer and President, Magenta Therapeutics. We are delighted to welcome Lisa and Kevin on board and look forward to their many contributions to the Magenta mission.

As Chief Scientific Officer, Dr. Olson will provide strategic direction, oversight and execution for Magentas research and discovery efforts. This entails driving research strategy as Magenta continues to optimize its preclinical and clinical pipeline. She will join the executive team and will be a key member of the R&D leadership team.

Dr. Olson is an experienced senior-level pharmaceutical executive, with more than 20 years of experience in research and drug discovery. She comes to Magenta following 15 years in leadership positions at the AbbVie Bioresearch Center, most recently as Vice President, Immunology Discovery and Site Head, where she was responsible for all immunology discovery scientific and portfolio decisions, including new target approval, project advancement and licensing opportunities. Under her leadership, 15 molecules advanced into clinical development, including Upadacitinib that launched last year as Rinvoq. Prior to AbbVie, she served as a Research Fellow and Group Leader in Inflammation & Immunology at Pfizer, Inc. She began her career as an Assistant Professor at Washington University School of Medicine, following a post-doctoral cardiovascular fellowship at the University of Chicago.

Dr. Olson holds a Ph.D. from the University of Illinois at Urbana-Champaign and a Bachelor of Science from Iowa State University.

As Senior Vice President, Head of Regulatory and Quality, Dr. Johnson will lead Magentas global regulatory strategy for the Companys programs across multiple therapeutic areas. He will also be responsible for the oversight and accountability for all quality activities to enable Good Practice (GxP) functions across the portfolio. In this role, Dr. Johnson will provide strategic guidance and leadership to members of the R&D leadership team and the regulatory and quality teams for Magentas portfolio for all phases of product lifecycle.

Dr. Johnson bring years of regulatory, quality assurance and development leadership, coming to Magenta from Imara, Inc., where he served as Senior Vice President, Regulatory Affairs, Quality and Pharmacovigilance, leading successful requests for several regulatory designations with the U.S. Food and Drug Administration (FDA). Prior to his time at Imara, Dr. Johnson led global regulatory strategy and implementation for breakthrough therapy-designated rare disease development programs at Vtesse, later acquired by Sucampo. He also served as Director, Global Regulatory Affairs for Rare Diseases and Gene Therapies at GlaxoSmithKline, where he was part of on the international regulatory team for the European approval of the gene therapy Strimvelis for ADA-SCID, and subsequently secured Regenerative Medicine Advanced Therapy (RMAT) designation for a retinal gene therapy product.

Dr. Johnson holds a Ph.D. in Neurobiology from the University of North Carolina (UNC) School of Medicine; a Master of Business Administration from the Kenan-Flagler School of Business, UNC; and a Bachelor of Science in Chemistry from the University of South Florida.

Along with these leadership team additions, Magenta also announced today that Jason Ryan, Chief Operating and Financial Officer, will step down from that role at the end of September. He will continue to contribute to Magenta in a consulting capacity, and the Company has commenced a search for a replacement.

Jason has been a dynamic and reliable leader at Magenta since he joined us in 2019, leading finance and operations, contributing to our strategic planning efforts, and spearheading two financings during a period of significant growth, said Gardner. We are truly grateful for his contributions to the patients we seek to serve, our employees and business partners.

About Magenta Therapeutics

Magenta Therapeutics is a clinical-stage biotechnology company developing medicines to bring the curative power of immune system reset through stem cell transplant to more patients with autoimmune diseases, genetic diseases and blood cancers. Magenta is combining leadership in stem cell biology and biotherapeutics development with clinical and regulatory expertise, a unique business model and broad networks in the stem cell transplant world to revolutionize immune reset for more patients.

Magenta is based in Cambridge, Mass. For more information, please visit http://www.magentatx.com.

Follow Magenta on Twitter: @magentatx.

Forward-Looking Statement

This press release may contain forward-looking statements and information within the meaning of The Private Securities Litigation Reform Act of 1995 and other federal securities laws. The use of words such as may, will, could, should, expects, intends, plans, anticipates, believes, estimates, predicts, projects, seeks, endeavor, potential, continue or the negative of such words or other similar expressions can be used to identify forward-looking statements. The express or implied forward-looking statements included in this press release are only predictions and are subject to a number of risks, uncertainties and assumptions, including, without limitation risks set forth under the caption Risk Factors in Magentas Annual Report on Form 10-K filed on March 3, 2020, as updated by Magentas most recent Quarterly Report on Form 10-Q and its other filings with the Securities and Exchange Commission. In light of these risks, uncertainties and assumptions, the forward-looking events and circumstances discussed in this press release may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. You should not rely upon forward-looking statements as predictions of future events. Although Magenta believes that the expectations reflected in the forward-looking statements are reasonable, it cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur. Moreover, except as required by law, neither Magenta nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements included in this press release. Any forward-looking statement included in this press release speaks only as of the date on which it was made. We undertake no obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law.

Read more from the original source:
Magenta Therapeutics Appoints Lisa M. Olson as Chief Scientific Officer and Kevin B. Johnson as Senior Vice President, Head of Regulatory and Quality;...

Immunology

This Free MIT Course Has Everything You Need To Know About COVID-19 – Well+Good

The pandemic has brought a barrage of news with so much information it can be overwhelming to understand whats going on (and to understand whats false). A new free online course from the Massachusetts Institute of Technology (MIT) serves to make that easier. COVID-19, SARS-CoV-2 and the Pandemic will walk you through the science of the pandemic with the help of a few familiar experts.

This MIT COVID-19 course is taught by professors Richard Young, PhD,and Facundo Batista, PhD, and will feature weekly guest lecturers like Anthony Fauci, MD. It explains the fundamentals of coronavirus and host cell biology, immunology, epidemiology, clinical disease, and vaccine and therapeutic development. Part of the course will cover lessons from the AIDS pandemic and the ins and outs of viral immunology.

The course will take place every Tuesday from 11:30 a.m. to 12:30 p.m. ET from September 1 through December 8. The course is open to allMIT students, any eligible cross-registered students, and the general public. Though the general public can view the classes, only students registered through the university will be able to ask questions.

To watch it live, click this link and enter the password mit-covid. If you miss a class, head to this page to view a recording. And be prepared to learn from professors at the top of their game.

Dr. Young is a geneticist who explores how and why gene expression differs in healthy versus diseased cells. He received his PhD from Yale University. In 2006, Scientific American recognized him as one of the top 50 leaders in science, technology and business. Hes also won a Burroughs Wellcome Scholarship, the Chiron Corporation Biotechnology Research Award, and Yales Wilbur Cross Medal. He has served as an advisor to Science magazine, the National Institutes of Health, and the World Health Organization.

Dr. Batista is a professor of microbiology and immunology at Harvard Medical School and the associate director of the Ragon Institute of Massachusetts General Hospital, MIT, and Harvard. He received his PhD from the International School of Advanced Studies in Trieste, Italy. He has served on the editorial boards of various journals, including Science. He is also the recipient of the Royal Society Wolfson Research Merit Award and a fellow of the UK Academy of Medical Sciences. In 2018, he was elected a fellow of the American Academy of Microbiology.

According to the syllabus, the course will cover:

Dr. Fauci will be a guest lecturer at the class covering the Insights from the COVID-19 pandemic on September 22. Dr. Fauci has served as the director of the National Institute of Allergy and Infectious Disease since 1984. He oversees an extensive portfolio of research to prevent, diagnose, and treat established infectious diseases such as HIV/AIDS, respiratory infections, diarrheal diseases, tuberculosis, and malaria.

Additional guest faculty include: Nobel laureate and biologist David Baltimore, PhD; neurosurgeon Victoria Clark, MD, PhD; immunologist Kizzmekia Corbett, PhD; biologist Britt Glaunsinger, PhD; immunobiologist Akiko Iwasaki, PhD; geneticist, molecular biologist, and mathematician Eric Lander, PhD; epidemiologist Michael Mina, PhD; molecular immunologist Michel Nussenzweig, MD, PhD; Shiv Pillai, MD, PhD; immunologist Arlene Sharp MD, PhD; immunologist Skip Virgin MD, PhD; and internal and infectious disease physician Bruce Walker, MD, PhD.

Excerpt from:
This Free MIT Course Has Everything You Need To Know About COVID-19 - Well+Good

Immunology

$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis – Washington…

Visit the News Hub

Researchers to study how immune cells respond after lung, heart transplants

Daniel Kreisel, MD, PhD, (right) the surgical director of lung transplantation at Washington University School of Medicine in St. Louis and Barnes-Jewish Hospital, is a principal investigator of two grants from the National Institutes of Health (NIH) totaling $10 million to study the prevention of organ rejection after transplantation. Kreisel is shown operating on a lung transplant patient with Varun Puri, MD, an associate professor of surgery and the associate surgical director of the lung transplant program.

Transplant surgeons and researchers at Washington University School of Medicine in St. Louis have received two grants totaling $10 million from the National Institutes of Health (NIH) to study how immune cells contribute to organ rejection, with the aim of improving the viability of organs after transplant.

A $7.7 million program project grant from the National Institute of Allergy and Infectious Diseases funds research to understand the immunological basis of lung transplant rejection.

And the National Heart, Lung, and Blood Institute awarded nearly $2.6 million to aid studies of the immune systems role in heart transplant rejection.

The ultimate goal is to improve the long-term outlook for lung and heart transplant patients, said Daniel Kreisel, MD, PhD, the surgical director of lung transplantation at the School of Medicine and Barnes-Jewish Hospital, and a principal investigator of both NIH grants. It is our hope that through our research, we will gain critical new insight into the immunological underpinnings of transplant tolerance and rejection.

Understanding how immune cells respond to transplanted organs sets the stage for developing novel therapeutic strategies to improve outcomes for transplant patients, said Kreisel, who is the G. Alexander Patterson, MD/Mid-America Transplant Endowed Distinguished Chair in Lung Transplantation.

For lung transplant patients, the risk of organ failure and death is particularly high. Five years after lung transplantation, about half of the lungs are still functioning, according to the U.S. Organ Procurement and Transplantation Network. This compares with five-year organ survival rates of about 70% for heart, liver and kidney transplants.

Uncovering the basis for the poor survival of lung transplant recipients should also give us new insight into the causes of other inflammatory diseases that affect the lung, said Andrew Gelman, PhD, a professor of surgery, and of immunology and pathology at Washington University and the Jacqueline G. and William E. Maritz Endowed Chair in Immunology and Oncology.

The funding will support three projects led by Kreisel, Gelman and Alexander S. Krupnick, MD, a professor of surgery and director of the lung transplant program at the University of Maryland that examine different immunological aspects of lung transplant tolerance. This refers to the ability of the immune system to recognize a transplanted lung as the bodys own.

Often, lung transplant remains the only option for patients with end-stage lung disease, a condition that can be brought on by emphysema, pulmonary fibrosis, cystic fibrosis and other lung disorders. Unlike other organs, lungs constantly are exposed to whatever is in the environment, including bacteria, viruses and air pollution. Such fragility contributes to the increased risk of chronic rejection and organ failure.

Also playing a key role in the research is Wenjun Li, MD, an associate professor of surgery and director of microsurgery in the Thoracic Immunobiology Laboratory. He is highly regarded among transplant scientists for developing microsurgical and imaging methods that have advanced the understanding of lung and heart transplantation.

For heart transplant patients, receiving a new heart is one of the most viable options for end-stage cardiovascular disease. About 3,550 people received a heart transplant from a deceased donor in 2019, according to the U.S. Organ Procurement and Transplantation Network.

However, heart transplant success can be threatened when the donor heart doesnt work properly. This complication called primary graft failure typically occurs in the early days following surgery and can prevent a newly transplanted heart from supplying enough blood to the bodys vital organs.

Current treatments have focused on targeting immune cells in the recipients heart. These have many side effects and are only modestly effective, said Kory J. Lavine, MD, PhD, a Washington University associate professor of medicine in the Cardiovascular Division and also one of the principal investigators. Our research will focus on alternative approaches based on targeting immune pathways and cell populations in the donor heart. We hope that insight gained from the research will result in new therapies that will increase donor heart availability and improve survival after heart transplantation.

Washington University School of Medicines 1,500 faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Childrens hospitals. The School of Medicine is a leader in medical research, teaching and patient care, ranking among the top 10 medical schools in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Childrens hospitals, the School of Medicine is linked to BJC HealthCare.

See the rest here:
$10 million in grants aimed at preventing organ rejection after transplantation Washington University School of Medicine in St. Louis - Washington...

Immunology

Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham – University of Birmingham

The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

A new test to detect COVID-19 antibodies in people with mild symptoms has been launched by The Binding Site in collaboration with the University of Birmingham's Clinical Immunology Service

The unique SARS-CoV-2 Antibody ELISA has been developed to identify individuals who have had a mild, non-hospitalised disease course following SARS-CoV-2 exposure. This latest development has brought together the Binding Site's extensive experience in developing highly precise, accurate blood tests with the expertise of leading immunology and immunity experts at the University of Birmingham

The new test specifically detects antibodies (IgG, IgA and IgM) to the SARS-CoV-2 trimeric spike protein, which is an important protein for the virus infectivity. The test was designed to detect all three immunoglobulins produced by the body to optimise the sensitivity and to increase detection at the earliest possible stage after exposure to the virus.

Professor Adam Cunningham, Professor of Functional Immunity at the University of Birmingham explains: Humans make three types of antibodies Anti-IgM, IgG and IgA. IgM tends to appear first, and IgG and lgA tend to appear later. By combining all three The Binding Site test is able to detect COVID-19 infection in people who have only mild symptoms of the disease.

The CE-marked ELISA test is simple to use and provides up to 93 test results in 60-90 minutes. The collaboration has shown that as well as through saliva or venous blood samples, the test can also detect antibodies in a dried blood spot. This means that the test can be developed into a finger prick test for home use, offering a more accurate testing capability in homes, businesses, airports as well as GP surgeries and hospitals in the UK and worldwide including low and middle income countries

Dr Stephen Harding, Chief Scientific Officer at The Binding Site said: We set out to develop a test with the University of Birmingham that would detect COVID-19 early, and validated the test in a non-hospitalised population that had mild symptoms which is the largest target population for COVID-19 testing - and we designed the testing kit so it can be used by any laboratory in the world.

The test was developed using over 800 blood samples taken from people who had mild to moderate disease. The test is already being used in many of the clinical studies conducted through the University of Birmingham including those focused on health care workers.

Charles de Rohan, CEO of The Binding Site, commented: The long-standing partnership with the University of Birmingham has brought together unrivalled academic, clinical and commercial expertise, and the combined team worked together seamlessly and quickly to deliver this unique and forward thinking test in record time.

Professor Alex Richter, Professor of Clinical Immunology at the University of Birmingham, who led the test development team, commented: There are two things to get right in an antibody test - which antibodies are we looking for, and what are they recognising? Testing for IgM, IgG and IgA antibodies to the spike protein should give an advantage in terms of early and accurate detection of people with recent exposure, who are not showing symptoms.

The Binding Site has provided free kits to support work in developing countries where the disease continues to spread quickly and is impacting on children through Paediatric Multisystem Inflammatory Syndrome (PIMS). The test has been submitted for rapid FDA approval and is expected to be available in quantities of over 2 million tests per month.

For more information please contact Sophie Belcher, Communications Manager, University of Birmingham, on +44 7815607157. Alternatively, contact the Press Office out of hours on +44 (0)7789 921165.

To hear more about the project please follow this link towatch a video

About the University of Birmingham

The University of Birmingham is ranked amongst the worlds top 100 institutions, and its work brings people from across the world to Birmingham, including researchers and teachers and more than 6,500 international students from nearly 150 countries.

About The Binding Site

Binding Site leads the way in specialist protein diagnostics. Built on strong scientific foundations with extensive expertise in antibody specificity technology, Binding Site gives clinicians and laboratory staff the tools to significantly improve diagnosis and management of patients across a range of cancers and immune system disorders.

The facility in Birmingham, UK, is their global headquarters, employing over 750 of its 1,100 total staff and housing all product development, manufacturing, global distribution and marketing. The Binding Site has a direct presence in over 25 countries and product sales through business partners in more than 100 countries.

Excerpt from:
Breakthrough antibodies test to detect COVID-19 cases launches in Birmingham - University of Birmingham

Immunology

UConn Health, CaroGen Collaborate on Promising Technology for Colorectal Cancer Treatment – UConn Today

Researchers at UConn Health and CaroGen Corporation, a biopharmaceutical company based at UConns Technology Incubation Program (TIP) facility in Farmington, have developed a promising clinical candidate for colorectal cancer treatment.

Kepeng Wang, assistant professor of immunology at UConn Health and a member of CaroGens Scientific Advisory Board, identified CARG-2020 as an oncolytic vector a virus that infects and kills cancer cells with the capacity to impact three critical cancer pathways.

Using CaroGens patented Artificial Virus for Infectious Diseases and Immune-Oncology (AVIDIO) platform, CARG-2020 targets three pathways by releasing an RNA expressing three immuno-modulators, each formulated to modify one of three pathways.

The novel benefit of CARG-2020 is that it can attack all three pathways at once. Scientists have previously had limited successes targeting these pathways individually.

They each carry out a unique function, Wang says. We think this combination approach will be the strongest immunology against cancer.

The first pathway, IL-17, promotes tumor growth and impedes the recruitment of anti-cancer Tcells. IL-12 is a cancer-fighting pathway normally shut down in tumors. It supports the development of Tcells. The PD-1 pathway also supports tumor growth by binding to Tcells and making these cells less active against tumors.

According to initial data, this approach is proving effective at not only regressing solid tumors, but preventing their regrowth.

Its really groundbreaking, Bijan Almassian, chief executive officer and co-founder of CaroGen, says. We hope to expand this collaboration and go beyond colorectal cancer.

The AVIDIO platform, developed by Yale University School of Medicine professor John Rose more than a decade ago, was licensed to CaroGen in 2012. The diverse platform has many applications in the treatment and prevention of cancer and infectious diseases.

CARG-2020 is also being tested in other solid tumors including ovarian and liver cancer. In addition, CaroGen is working with scientists from Yale to develop a COVID-19 vaccine using AVIDIO.

Wangs lab has been working with CaroGen since 2016 when professor and chair of immunology at UConn Health, Anthony Vella, introduced them.

We work very well together and Im very proud to be part of that, Wang says.

This collaboration outlines a fruitful business model in which research labs and corporations support one anothers missions for the overall advancement of science.

UConn Health is a source of a lot of innovation and great science, and collaboration is easy, given our location at UConns business incubator, the Technology Incubation Program (TIP), Almassian says.

The next steps for CARG-2020 are to seek funding to bring it into a clinical trial setting.

Its been extremely productive and efficient, Almassian says. Were addressing a major unmet medical need.

Wang holds a Ph.D. in biochemistry from the Hong Kong University of Science and Technology. His research focuses on the role of interleukin-17 (IL-17) family cytokines in colorectal cancer development and therapeutic intervention.

Follow UConn Research on Twitter & LinkedIn.

Read this article:
UConn Health, CaroGen Collaborate on Promising Technology for Colorectal Cancer Treatment - UConn Today

Immunology

Global immunology market size was valued at USD 77365.4 Million in 2018 and is projected to reach USD 143833.2 Million by 2026, exhibiting a CAGR of…

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Immunology market.

Trusted Business Insights presents an updated and Latest Study on Immunology Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Immunology market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

The global immunology market size was valued at USD 77,365.4 Million in 2018 and is projected to reach USD 143,833.2 Million by 2026, exhibiting a CAGR of 8.1% in the forecast period.

We have updated Immunology Market with respect to COVID-19 Impact.Inquire before buying

Existing market players operating in the global immunology market are focusing on constant innovations and up-gradation of their product portfolio with new and efficient product offerings for better treatment outcomes for the patients. One of the primary reasons for the growth of the global market is the increasing incidence of immunological and autoimmune diseases. Rise in awareness regarding immunological diseases in both developing and developed nations, and the higher prevalence of immunological disorders due to environmental factors, thus propelling the of the global immunology market growth. This, coupled with, increasing investments by major players in research and development activities are also boosting the growth of the market globally.

The change in the immunology market share is also primarily driven by a greater focus towards the R&D initiatives due to recent regulatory approvals, increasing trends of patent expiry and the subsequent emergence of comparatively cheaper biosimilars. Some of the other factors which are also contributing to the growth of the market are the increase in the efficiency of the immunology drugs leading to better patient outcomes and improved quality of life.

The introduction of new and sophisticated targeted therapies such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG is expected to drive the growth of the immunology market in developed as well as emerging countries, during the forecast period 2019-2026.

Increasing adoption of monoclonal antibody (mAb), combined with the increasing prevalence of immunological diseases is driving the growth of the global market

Increasing adoption and demand for monoclonal antibody (mAb), which is the drug class of a number of immunology drugs and has a number of associated advantages such as its status as a high specific therapy, is one of the most prominent driving factors for the growth of the global immunology industry in 2018. Increasing R&D initiatives in the monoclonal antibody segment and a large number of drugs under the segment is also driving the growth in the monoclonal antibody (mAb) segment.

The immunosuppressant segment is estimated to grow at a faster CAGR during the forecast period. This is attributed to the anticipated increase in the revenue under this drug class, with the interleukin inhibitors becoming more prominent in the immunology market trend. Currently, there is increasing adoption of the immunosuppressants in the markets in the developing nations due to its higher achievement in terms of the efficient treatment leading to improved patient outcomes, and this is expected to contribute to the growth of the market at higher CAGRs during the forecast period.Market Segmentation

Based on the drug class, the global immunology market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb), and others. Monoclonal antibody (mAb) segment is estimated to have the largest market share among the drug class types.

The targeted therapy segment accounted for a market share of 64.5% in 2018 and is expected to rise during the forecast period. Based on disease indication, the global market segments include rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection, and others. Based on the distribution channel, the global immunology industry segments include hospital pharmacies, retail pharmacies, online pharmacies, and others.

Regional Analysis

Growing Prevalence and Awareness of Autoimmune and Immunological Disorders and Increasing Adoption of Immunology Drugs Expected to Result in The Highest CAGR in the Asia PacificNorth America generated a revenue of US$ 41,622.5 Mn in 2018 and is anticipated to account for a dominant share in the global market during the forecast period. The immunology market growth witnessed in the region is likely to be driven by the increasing adoption of advanced immunology drugs and rising prevalence of autoimmune and immunological disorders.

This is especially applicable in instances where there is a steady escalation of the symptoms and the disease progresses due to lack of efficient treatment. In developed countries, the adoption of advanced immunology drugs such as immunosuppressants is increasing along with the existing drug classes of monoclonal antibody (mAb) and polyclonal antibody (pAb) amongst others.North America Immunology Market, 2018

Europe is estimated to be the second most dominant market after North America due to substantial R&D initiatives and adoption of advanced immunology drugs. Whereas, in emerging countries such as India and China, the rise in awareness of autoimmune and immunological disorders is fueling growth in the immunology market during the forecast period.

In countries like China and India, there is an existing conflict with the high prices attached to some of the immunology drugs. However, in countries like Japan, there is increased adoption and expenditure towards advanced immunology drugs. The Latin America and Middle East & Africa market is also estimated to have future growth potential in global immunology market growth.

Key Market Drivers

AbbVie Inc., Johnson & Johnson, and Roche dominated the global immunology market in 2018 AbbVie Inc., emerged as the leading player with the highest market share in 2018, as the company has the patent rights to HUMIRA (adalimumab), the worlds best-selling drug. The drug accounts for the highest revenue shares in the immunology segment and is approved for a number of disease indications including rheumatoid arthritis and psoriatic arthritis. In addition, other market players are also getting product approvals such as TREMFYA by Janssen Global Services, LLC (Johnson & Johnson) and Cosentyx by Novartis AG. Other players operating in the Immunology market are Janssen Global Services, LLC (Johnson & Johnson), F. Hoffmann-La Roche Ltd, Amgen Inc., Pfizer Inc., Novartis AG, Astellas, Bristol-Myers Squibb Company, Merck Sharp & Dohme Corp., UCB SA, and ALLERGAN.

List of Companies Profiled

Report Coverage

The increasing prevalence of a number of autoimmune and immunological disorders in the general population is one of the key factors boosting the global immunology market revenue. The increasing R&D initiatives in the immunology industry and the recent regulatory approvals are also positively contributing to the growth of the market. The introduction of new products in the market, along with an increasing number of patients undergoing treatment for immunological diseases globally is projected to further augment the demand for immunology drugs during the forecast period.

The report provides qualitative and quantitative insights on the immunology industry trends and detailed analysis of immunology market size and growth rate for all possible segments in the market. The market segments include drug class, disease indication, distribution channel, and geography.

On the basis of the drug class, the global market segments include monoclonal antibody (mAb), fusion proteins, immunosuppressants, polyclonal antibody (pAb) and others. On the basis of disease indication, the market is categorized into rheumatoid arthritis, psoriatic arthritis, plaque psoriasis, ankylosing spondylitis, inflammatory bowel disease, prophylaxis of organ rejection and others. On the basis of the distribution channel, the immunology industry is categorized into hospital pharmacies, retail pharmacies, online pharmacies, and others.Along with this, the report analysis includes market dynamics and competitive landscape. Various key insights provided in the report are the prevalence of autoimmune and immunological disorders by key countries, regulatory scenario by key regions, key industry developments, overview of regulatory scenario by key countries, an overview of current advances in R&D for immunology.

SEGMENTATION

By Drug Class

By Disease Indication

By Distribution Channel

By Geography

Key Industry Developments

In April 2019, Novartis AGs product offering of Cosentyx (secukinumab) for the treatment of moderate to severe psoriasis was approved in China

In April 2019, AbbVie Inc. extended their immunology portfolio with the launch of their new product offering of SKYRIZI (risankizumab-rzaa) for the treatment of moderate to severe plaque psoriasis

In July 2017, Janssen Global Services, LLC (Johnson & Johnson) announced the launch of TREMFYA (guselkumab) for the treatment of moderate to severe plaque psoriasis

Looking for more? Check out our repository for all available reports on Immunology in related sectors.

Quick Read Table of Contents of this Report @ Immunology Market Size, Share and Industry Analysis By Drug Class (Monoclonal antibody (mAb), Fusion Proteins, Immunosuppressant, Polyclonal antibody (pAb), Others), By Disease Indication (Rheumatoid Arthritis, Psoriatic Arthritis, Plaque Psoriasis, Ankylosing Spondylitis, Inflammatory Bowel Disease, Prophylaxis of Organ Rejection, Others), By Distribution Channel, and Regional Forecast 2020-2029 (Includes COVID-19 Business Impact)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

More:
Global immunology market size was valued at USD 77365.4 Million in 2018 and is projected to reach USD 143833.2 Million by 2026, exhibiting a CAGR of...

Immunology

Global Immunology Drug Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Abbott Laboratories, Active Biotech, Eli Lilly and Company,…

The Global Immunology Drug Size, Status and Forecast 2020-2026 market report covers deep insights into factors such as the COVID-19, which is likely to have an impact on the market. Moreover, it also covers several aspects such as a detailed analysis of the market in the estimated forecast period. In addition, it covers aspects such as the market share and market analysis which is likely to be affected by the global pandemic of COVID-19.

Following Top Key Players are profiled with global positioning:

Get Free Sample PDF (including full TOC, Tables and Figures) of Immunology Drug Market @ https://www.innovateinsights.com/report/global-immunology-drug-market-by-type-monoclonal-antibodies/324077/#requestsample

The report also highlights several aspects of the segments which are being covered in the market. Some of the segments in the Immunology Drug market consist of Immunology Drug. In the past few months, the demand for these masks has escalated, which can be attributed to the effect of the COVID-19. In addition, there have been several strategies and tools which are being covered in the Immunology Drug Market to determine the effect of the pandemic. Among the several strategies which are being used, some of them are the most widely used strategies such as the SWOT and PESTLE analysis.

Global Immunology Drug Market Segmentation By Type:

Global Immunology Drug Market Segmentation By Applications:

Global Immunology Drug Market Segmentation By Regions:

North America (U.S., Canada, Mexico) South America (Cuba, Brazil, Argentina, and many others.) Europe (Germany, U.K., France, Italy, Russia, Spain, etc.) Asia (China, India, Russia, and many other Asian nations.) Pacific region (Indonesia, Japan, and many other Pacific nations.) Middle East & Africa (Saudi Arabia, South Africa, and many others.)

Place Inquiry for Buying or Customization of Report: https://www.innovateinsights.com/report/global-immunology-drug-market-by-type-monoclonal-antibodies/324077/#buyinginquiry

These strategies help in the determination and the impact of the COVID-19 on the companies and manufacturers. SWOT analysis is being used for the determination of the various segments of the market. It involves the use of the strengths, weakness, and, threats which are being covered for the market. Moreover, the report also covers the various aspects of the consumers which involve the purchasing patterns, spending patterns, and, geographical patterns. The impact of the pandemic on these aspects has been explained in the report. The Immunology Drug research report also covers and conducts the interviews and analyses the growth of the market for the estimated growth of the market. Moreover, the impact of COVID-19 in the upcoming years has also been covered in the research study.

ACCESS FULL REPORT: https://www.innovateinsights.com/report/global-immunology-drug-market-by-type-monoclonal-antibodies/324077/

As the industry analysts estimates and extracts the data which are affecting the growth of the market which is being affected by the pandemic of COVID-19. In addition, it also covers the demand and supply of the market and the effects and impact of the pandemic in the estimated forecast period. Moreover, increased demand from the consumers in the pandemic also affects the market. The research study has also analyzed several major manufacturers that are present in the Immunology Drug market. It is also used for the determination of the market share and the revenues which are being affected by the global COVID-19 pandemic. Moreover, the products and the application which are being used by the consumers are also studied. Moreover, the overall impact of COVID-19 has also been analyzed and estimated, which are some of the major attributes which are covered in the research reports.

Chapters Define in TOC (Table of Content) of the Report:

Chapter 1: Market Overview, Drivers, Restraints and Opportunities, Segmentation overviewChapter 2: Market Competition by ManufacturersChapter 3: Production by RegionsChapter 4: Consumption by RegionsChapter 5: Production, By Types, Revenue and Market share by TypesChapter 6: Consumption, By Applications, Market share (%) and Growth Rate by ApplicationsChapter 7: Complete profiling and analysis of ManufacturersChapter 8: Manufacturing cost analysis, Raw materials analysis, Region-wise manufacturing expenses.Chapter 9: Industrial Chain, Sourcing Strategy and Downstream BuyersChapter 10: Marketing Strategy Analysis, Distributors/TradersChapter 11: Market Effect Factors AnalysisChapter 12: Market ForecastChapter 13: Immunology Drug Research Findings and Conclusion, Appendix, methodology and data source.

Read more:
Global Immunology Drug Market 2020 to Witness Huge Growth by 2026 | Top Key Players; Abbott Laboratories, Active Biotech, Eli Lilly and Company,...

Immunology

COVID-19 Data Dives: Preexisting Immunity to SARS-CoV-2 Is a Thing – Medscape

Medscape asked top experts to weigh in on the most pressing scientific questions about COVID-19. Check back frequently for more COVID-19 Data Dives, and visit Medscape's Coronavirus Resource Center for complete coverage.

Adam Kucharski, MMath, PhD

There are now several studies that, taken together, give us a useful indication of the possible role of preexisting immunity (antibodies/T cells, etc.) in SARS-CoV-2 dynamics.

Here are my thoughts, plus some helpful links, on the matter.

First, there are several well-defined outbreaks in which a very large percentage of people had detectable infection (either a positive PCR or detectable antibody levels). There were 103 cases out of 117 people on a fishing boat, 11 out of 13 individuals who attended the same meeting, and 7 out of 8 and then 8 out of 8 of those who ate a meal together.

This would suggest that there is not a substantial percentage of the adult population that cannot get infected if exposed to this novel coronavirus. This conclusion is consistent with other data from healthcare workers and care homes.

If there is enough exposure and you look hard enough, it seems you will find infections.

But just because the majority of people are vulnerable to infection does not mean that there is no immunity at all. In a study of individuals during the previously mentioned outbreak on the fishing boat, a small number (3 out of 120) had neutralizing antibodies, perhaps from earlier SARS-CoV-2 infection. They did not get infected again.

Then there's children. There is evidence that they may be less susceptible to infection. Some younger kids not previously exposed to SARS-CoV-2 also have cross-reactive antibodies, which may help explain the reduced risk.

So far we've been talking about immunity against infection. However, there is also the question of protection against disease. Clearly some people get less severe symptoms, suggesting some role of disease immunity.

There's evidence of some pre-existing T-cell responses in individuals who have not been infected with SARS-CoV-2. For people who have been infected with SARS-CoV-2, T-cell responses can persist after infection.

This would be good news, and consistent with circulating seasonal "common cold" coronaviruses, which can reinfect people but seem to result in milder symptoms on reinfection.

It's important to note that protection from infection affects epidemic dynamics more than protection from disease. In herd immunity calculations, what matters is whether people transmit, not how ill they get (although the two may be correlated). So immunity against disease won't necessarily stop outbreaks.

It's also worth remembering that any preexisting immunity from infection (eg, among children) is already "priced into" the reproduction number; the rapid growth early in the pandemic would have been in spite of any preexisting immunity. So we need to be careful about interpreting how immunity might influence dynamics.

Obviously there's still a lot more we need to learn about SARS-CoV-2 immunity. I will be interested to hear about any other emerging studies that shed light on this issue (or whether immunologists want to flag anything I've missed).

For those of you particularly interested in this issue, I would recommend a useful primer published in The Atlantic written by Ed Yong, a science writer, about why these immunology questions are important and very challenging.

Adam Kucharski is an epidemiologist whose research focuses on the dynamics of infectious diseases, including how social behavior and immunity shape disease transmission, and how knowledge of such processes can enhance control measures. Follow him on Twitter

Follow Medscape on Facebook, Twitter, Instagram, and YouTube

Here is the original post:
COVID-19 Data Dives: Preexisting Immunity to SARS-CoV-2 Is a Thing - Medscape